Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06859294 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
A Phase 2 study of Rheumatoid Arthritis, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 20
- Study locations
NCT06859294: Active Phase 2 study of Rheumatoid Arthritis, sponsored by Eli Lilly and Company.
NCT06859294 is a Phase 2 study of Rheumatoid Arthritis that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 35 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06859294, a Phase 2 study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
Primary Outcome
DAS28-hsCRP measures disease activity in 28 joints using a composite numeric score. Total scores range from 1.0 to 9.4, where a lower score indicates less disease activity.
Conditions Studied
Interventions
- DRUG LY3541860
Study Locations (20)
Arizona
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale - Avondale
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff - Flagstaff
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa - Mesa
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV - Phoenix
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City - Sun City
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast - Tucson
California
- Medvin Clinical Research - Covina - Covina
- Newport Huntington Medical Group - Huntington Beach
- Medvin Clinical Research - Tujunga - Tujunga
- Medvin Clinical Research - Whittier - Whittier
Florida
- Clinical Research of West Florida, Inc. (Clearwater) - Clearwater
- Clinical Research of West Florida - Tampa
- Conquest Research - Winter Park
Texas
- Accurate Clinical Management, LLC - Baytown
- Accurate Clinical Research, Inc - Houston
- DM Clinical Research - TRA - Tomball
Illinois
- Willow Rheumatology and Wellness PLLC - Willowbrook
Louisiana
- Accurate Clinical Research, Inc - Lake Charles
Minnesota
- Saint Paul Rheumatology - Eagan
Pennsylvania
- Altoona Center For Clinical Research - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT06859294 still lists
NCT06859294 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which LY3541860 is the first listed.
NCT06859294 names 20 study sites across 8 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06859294 about?
NCT06859294 is a clinical study titled "A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis". The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic dru...
What is the current status of trial NCT06859294?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-03-19. Estimated completion is 2026-09.
What conditions does trial NCT06859294 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06859294?
The interventions under investigation include: LY3541860 (DRUG).
Who is sponsoring clinical trial NCT06859294?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06859294 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06859294's enrollment target sits among peer trials
35 153rd of 197 higher than 45 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI